Tom 13, Nr 1 (2018)
Artykuł przeglądowy
Opublikowany online: 2018-03-22
Wyświetlenia strony
1056
Wyświetlenia/pobrania artykułu
2855
Rola galektyny 3 jako markera diagnostycznego i prognostycznego w kardiologii
DOI: 10.5603/FC.2018.0005
Folia Cardiologica 2018;13(1):29-34.
Streszczenie
Galektyna-3 (Gal-3) jest białkiem należącym do rodziny lektyn. Produkowana jest pod wpływem czynników zapalnych przez różnego rodzaju komórki, m.in. związane bezpośrednio z rozwojem miażdżycy jak np. makrofagi i komórki śródbłonka naczyniowego. Galektyna-3 jest biomarkerem związanym z zapaleniem i włóknieniem mięśnia sercowego u chorych z niewydolnością serca. Związek Gal-3 z czynnikami ryzyka sercowo-naczyniowego pozwala sądzić, że jest ona również obiecującym parametrem w ocenie rozwoju miażdżycy. Dotychczasowe badania sugerują, że może być ona przydatnym markerem w diagnostyce oraz ocenie rokowania zarówno w chorobie niedokrwiennej serca jak i niewydolności serca.
Słowa kluczowe: Galektyna-3miażdżycaczynniki ryzyka sercowo-naczyniowegochoroba niedokrwienna sercaniewydolność serca.
Referencje
- Bazaeva EV, Myasnikov RP, Metelskaya VA, et al. [Diagnostic Value of Biochemical Markers in Patients With Chronic Heart Failure With Reduced, Borderline and Preserved Left Ventricular Ejection Fraction]. Kardiologiia. 2017; 57(3): 39–45.
- Aksan G, Gedikli Ö, Keskin K, et al. Is galectin-3 a biomarker, a player-or both-in the presence of coronary atherosclerosis? J Investig Med. 2016; 64(3): 764–770.
- Sharma UC, Mosleh W, Chaudhari MR, et al. Myocardial and Serum Galectin-3 Expression Dynamics Marks Post-Myocardial Infarction Cardiac Remodelling. Heart Lung Circ. 2017; 26(7): 736–745.
- Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006; 1760(4): 616–635.
- Argüeso P, Panjwani N. Focus on molecules: galectin-3. Exp Eye Res. 2011; 92(1): 2–3.
- de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009; 11(9): 811–817.
- Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010; 12(8): 826–832.
- Ozturk D, Celik O, Satilmis S, et al. Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. Coron Artery Dis. 2015; 26(5): 396–401.
- He XW, Li WL, Li C, et al. Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke. Sci Rep. 2017; 7: 40994.
- Imran TF, Shin HJ, Mathenge N, et al. Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population. Am J Cardiol. 2017; 119(1): 57–64.
- Winter MP, Wiesbauer F, Alimohammadi A, et al. Soluble galectin-3 is associated with premature myocardial infarction. Eur J Clin Invest. 2016; 46(5): 386–391.
- Jin Qh, Lou Yf, Li Tl, et al. Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus. Chin Med J (Engl). 2013; 126(11): 2109–2115.
- Medvedeva EA, Berezin II, Shchukin YV, et al. [Galectin-3, Markers of Oxidative Stress and Renal Dysfunction in Patients With Chronic Heart Failure]. Kardiologiia. 2017; 57(3): 46–50.
- McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med. 2011; 12(4): 200–210.
- Medvedeva EA, Berezin II, Surkova EA, et al. Galectin-3 in patients with chronic heart failure: association with oxidative stress, inflammation, renal dysfunction and prognosis. Minerva Cardioangiol. 2016; 64(6): 595–602.
- Chen K, Jiang RJ, Wang CQ, et al. Predictive value of plasma galectin-3 in patients with chronic heart failure. Eur Rev Med Pharmacol Sci. 2013; 17(8): 1005–1011.
- Stoltze Gaborit F, Bosselmann H, Kistorp C, et al. Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. BMC Cardiovasc Disord. 2016; 16: 117.
- Lisowska A, Knapp M, Tycińska A, et al. Predictive value of Galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: A mid-term prospective cohort study. Atherosclerosis. 2016; 246: 309–317.
- Amin HZ, Amin LZ, Wijaya IP. Galectin-3: a novel biomarker for the prognosis of heart failure. Clujul Med. 2017; 90(2): 129–132.
- Zhang R, Zhang Y, An T, et al. Prognostic value of sST2 and galectin-3 for death relative to renal function in patients hospitalized for heart failure. Biomark Med. 2015; 9(5): 433–441.
- Stolen CM, Adourian A, Meyer TE, et al. Plasma galectin-3 and heart failure outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). J Card Fail. 2014; 20(11): 793–799.
- Gandhi PU, Motiwala SR, Belcher AM, et al. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. Am Heart J. 2015; 169(3): 404–411.e3.
- Sanders-van Wijk S, Masson S, Milani V, et al. TIME-CHF Investigators and the GISSI-HF Investigators. Interaction of Galectin-3 Concentrations with the Treatment Effects of β-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HF. Clin Chem. 2016; 62(4): 605–616.
- Gullestad L, Ueland T, Kjekshus J, et al. CORONA Study Group. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J. 2012; 33(18): 2290–2296.
- Anand IS, Rector TS, Kuskowski M, et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail. 2013; 15(5): 511–518.
- Calvier L, Legchenko E, Grimm L, et al. Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. Heart. 2016; 102(5): 390–396.
- Filipe MD, Meijers WC, Rogier van der Velde A, et al. Galectin-3 and heart failure: prognosis, prediction & clinical utility. Clin Chim Acta. 2015; 443: 48–56.
- Yancy CW, Jessup M, Bozkurt B, et al. WRITING COMMITTEE MEMBERS, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128(16): e240–e327.
- Lala RI, Lungeanu D, Darabantiu D, et al. Galectin-3 as a marker for clinical prognosis and cardiac remodeling in acute heart failure. Herz. 2017 [Epub ahead of print].
- Sudharshan S, Novak E, Hock K, et al. Use of Biomarkers to Predict Readmission for Congestive Heart Failure. Am J Cardiol. 2017; 119(3): 445–451.
- Falcone C, Lucibello S, Mazzucchelli I, et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol. 2011; 24(4): 905–913.
- Milner TD, Viner AC, MacKinnon AC, et al. Temporal expression of galectin-3 following myocardial infarction. Acta Cardiol. 2014; 69(6): 595–602.
- Kruk M, Menon V, Kądziela J, et al. Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the Occluded Artery Trial (OAT) biomarker ancillary study. BMC Cardiovasc Disord. 2013; 13: 91.
- Bivona G, Bellia C, Lo Sasso B, et al. Short-term Changes in Gal 3 Circulating Levels After Acute Myocardial Infarction. Arch Med Res. 2016; 47(7): 521–525.
- Jansen H, Koenig W, Jaensch A, et al. Prognostic Utility of Galectin-3 for Recurrent Cardiovascular Events During Long-term Follow-up in Patients with Stable Coronary Heart Disease: Results of the KAROLA Study. Clin Chem. 2016; 62(10): 1372–1379.
- A VA, Zaslavskaya EL, Soboleva AV, et al. [Galectin-3 in Patients With Paroxysmal and Persistent Atrial Fibrillation and Metabolic Syndrome]. Kardiologiia. 2016; 56(6): 41–45.
- Kocyigit D, Gurses KM, Yalcin MU, et al. Serum galectin-3 level as a marker of thrombogenicity in atrial fibrillation. J Clin Lab Anal. 2017; 31(6).
- Clementy N, Benhenda N, Piver E, et al. Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial Fibrillation. Sci Rep. 2016; 6: 34357.
- Gawor M, Śpiewak M, Janas J, et al. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy. Kardiol Pol. 2017; 75(10): 997–1004.
- Oz F, Onur I, Elitok A, et al. Galectin-3 correlates with arrhythmogenic right ventricular cardiomyopathy and predicts the risk of ventricular -arrhythmias in patients with implantable defibrillators. Acta Cardiol. 2017; 72(4): 453–459.
